332 related articles for article (PubMed ID: 19289760)
1. Neurolymphomatosis associated with Sézary syndrome.
Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
[TBL] [Abstract][Full Text] [Related]
2. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
3. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides and Sezary syndrome against a human immunodeficiency virus-positive background: case report.
Gahongayire F
Int J Dermatol; 2007 Oct; 46 Suppl 1():32-5. PubMed ID: 17919204
[TBL] [Abstract][Full Text] [Related]
5. [Sézary syndrome with ascitis: case report and review of the literature].
Nubourgh I; Van den Broeck K; Bradstreet C; Praet JP; Cantinieaux B
Rev Med Brux; 2005; 26(5):445-50. PubMed ID: 16318098
[TBL] [Abstract][Full Text] [Related]
6. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
[TBL] [Abstract][Full Text] [Related]
7. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
8. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sézary syndrome.
D'Incan M; Souteyrand P; Bignon YJ; Fonck Y; Roger H
Arch Dermatol; 1992 Oct; 128(10):1371-4. PubMed ID: 1417026
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
10. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
11. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
12. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
Tan ES; Tang MB; Tan SH
Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
[TBL] [Abstract][Full Text] [Related]
13. [Renal insufficiency caused by leukemic cell infiltration in Sézary syndrome].
Tanaka Y; Nagai K; Tani M; Watanabe N; Kurata M; Matsushita A; Maeda A; Yamashita E; Shirane H; Takahashi T
Rinsho Ketsueki; 2005 May; 46(5):368-71. PubMed ID: 16444971
[TBL] [Abstract][Full Text] [Related]
14. Sézary syndrome in a Malay--case report and literature review.
Yuen P; Chan HL; Lee YS
Singapore Med J; 2001 May; 42(5):224-7. PubMed ID: 11513062
[TBL] [Abstract][Full Text] [Related]
15. Sézary syndrome. A malignant leukemic reticuloendotheliosis.
Tedeschi LG; Lansinger DT
Arch Dermatol; 1965 Sep; 92(3):257-62. PubMed ID: 11851246
[TBL] [Abstract][Full Text] [Related]
16. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome.
Curry JL; Prieto VG; Jones DM; Vega F; Duvic M; Diwan AH
J Cutan Pathol; 2011 Mar; 38(3):295-7. PubMed ID: 19889052
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
18. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
19. [Sézary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate].
Hirayama Y; Nagai T; Ohta H; Koyama R; Matsunaga T; Sakamaki S; Niitsu Y
Rinsho Ketsueki; 2000 Sep; 41(9):750-4. PubMed ID: 11070938
[TBL] [Abstract][Full Text] [Related]
20. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
So CC; Wong KF; Siu LL; Kwong YL
Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
